Meng Zhang1, Xin Xu1, Wei Liu1, Zhongwei Zhang1, Qiuyu Cheng1, Zhongyuan Yang1, Tingting Liu1, Yunhui Liu1, Qin Ning1, Tao Chen2, Junying Qi3. 1. Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095, Jiefang Avenue, Wuhan, 430030, People's Republic of China. 2. Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095, Jiefang Avenue, Wuhan, 430030, People's Republic of China. chentao_tjh@vip.sina.com. 3. Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095, Jiefang Avenue, Wuhan, 430030, People's Republic of China. jyqi007@126.com.
Abstract
INTRODUCTION: Spontaneous bacterial peritonitis (SBP) is a common infection in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF). SBP significantly increases the mortality rate and medical costs. The association between proton pump inhibitor (PPI) use and SBP remains unclear. We conducted a retrospective study to investigate the association between PPI use and SBP in patients with HBV-related ACLF and to explore the risk factors for SBP. METHODS: We compared the SBP incidence between the PPI and non-PPI groups before and after propensity score matching and explored the association between the duration and type of PPI and SBP occurrence. Risk factors for SBP occurrence were determined by univariate and multivariate logistic regression analysis. RESULTS: The SBP incidence was higher in the PPI group than in the non-PPI group before and after propensity score matching. The SBP incidence increased for elevated MELD scores in PPI users. There was a similar SBP incidence in both different types and durations of PPI users. MELD score, old age, male sex, and high WBC count were significant independent risk factors for SBP in PPI users with HBV-related ACLF in the hospital. CONCLUSIONS: PPI therapy increases the risk of SBP development in patients with HBV-related ACLF. MELD score, old age, male sex, and high WBC count could serve as predictors of SBP in PPI users. Caution should be taken regarding PPI use, especially for patients with MELD scores > 30.
INTRODUCTION: Spontaneous bacterial peritonitis (SBP) is a common infection in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF). SBP significantly increases the mortality rate and medical costs. The association between proton pump inhibitor (PPI) use and SBP remains unclear. We conducted a retrospective study to investigate the association between PPI use and SBP in patients with HBV-related ACLF and to explore the risk factors for SBP. METHODS: We compared the SBP incidence between the PPI and non-PPI groups before and after propensity score matching and explored the association between the duration and type of PPI and SBP occurrence. Risk factors for SBP occurrence were determined by univariate and multivariate logistic regression analysis. RESULTS: The SBP incidence was higher in the PPI group than in the non-PPI group before and after propensity score matching. The SBP incidence increased for elevated MELD scores in PPI users. There was a similar SBP incidence in both different types and durations of PPI users. MELD score, old age, male sex, and high WBC count were significant independent risk factors for SBP in PPI users with HBV-related ACLF in the hospital. CONCLUSIONS: PPI therapy increases the risk of SBP development in patients with HBV-related ACLF. MELD score, old age, male sex, and high WBC count could serve as predictors of SBP in PPI users. Caution should be taken regarding PPI use, especially for patients with MELD scores > 30.
Authors: Javier Fernández; Verónica Prado; Jonel Trebicka; Alex Amoros; Thierry Gustot; Reiner Wiest; Carme Deulofeu; Elisabet Garcia; Juan Acevedo; Valentin Fuhrmann; François Durand; Cristina Sánchez; Maria Papp; Paolo Caraceni; Victor Vargas; Rafael Bañares; Salvatore Piano; Martin Janicko; Agustin Albillos; Carlo Alessandria; German Soriano; Tania M Welzel; Wim Laleman; Alexander Gerbes; Andrea De Gottardi; Manuela Merli; Minneke Coenraad; Faouzi Saliba; Marco Pavesi; Rajiv Jalan; Pere Ginès; Paolo Angeli; Vicente Arroyo Journal: J Hepatol Date: 2018-11-02 Impact factor: 25.083
Authors: Javier Fernández; Juan Acevedo; Reiner Wiest; Thierry Gustot; Alex Amoros; Carme Deulofeu; Enric Reverter; Javier Martínez; Faouzi Saliba; Rajiv Jalan; Tania Welzel; Marco Pavesi; María Hernández-Tejero; Pere Ginès; Vicente Arroyo Journal: Gut Date: 2017-08-28 Impact factor: 23.059
Authors: Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo Journal: Gastroenterology Date: 2013-03-06 Impact factor: 22.682